US measles cases hit 35‑year high; biotech races to forge treatments

US measles cases spark biotech response

The surge in US measles cases has forced a rare shift from prevention to cure, as companies scramble to develop antivirals and short‑term prophylaxis. Recent outbreaks in South Carolina and Utah pushed the tally beyond ↑ 35% the previous year, eclipsing the Reuters‑reported 2,289 cases well before July. Vaccination coverage slipped ↓ 12% amid growing hesitancy, leaving pockets of the population vulnerable.

“Without a vaccine, therapeutic options become a public‑health imperative,” said a leading epidemiologist.

Academic labs and start‑ups alike are leveraging monoclonal antibodies and RNA‑based inhibitors, but clinical trials will not conclude for several years. Even if approved, uptake among anti‑vaccine communities remains uncertain. The looming question: can treatment replace prevention, or will it merely buy time while public‑trust campaigns falter?